Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 16/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4312620 | 0.85 | BACE1 (0.37) | ALDH1A1MEN1MAPTKMT2ABACE1 | |
| SCHEMBL14327930 | 0.84 | P2RX3 (0.39) | MAPT | |
| SCHEMBL16953353 | 0.82 | ALDH1A1 (0.35) | ALDH1A1MEN1MAPTKMT2ABACE1 | |
| SCHEMBL16781415 | 0.82 | AR (0.43) | ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL31004959 | 0.81 | PDE4B (0.43) | ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL13932862 | 0.81 | ALDH1A1 (0.38) | ALDH1A1MEN1MAPTKMT2ABACE1 | |
| SCHEMBL8534821 | 0.80 | KMT2A (0.31) | ALDH1A1MEN1MAPTKMT2ABACE1 | |
| SCHEMBL27801351 | 0.79 | ALDH1A1 (0.39) | ALDH1A1MEN1MAPTKMT2ABACE1 | |
| SCHEMBL4312387 | 0.79 | MEN1 (0.32) | ALDH1A1MEN1KMT2ABACE1 | |
| SCHEMBL4315907 | 0.79 | MAPT (0.41) | ALDH1A1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210101879-A1 | AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIs) FOR ALZHEIMER?S DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-04-08 | — | — | US | disclosed |
| US-20210101879-A1 | AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIs) FOR ALZHEIMER?S DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-04-08 | — | — | US | disclosed |
| EP-3759079-A1 | AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIS) FOR ALZHEIMER'S DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-01-06 | — | — | EP | disclosed |
| US-20200165225-A1 | BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | NANTBIO, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| WO-2019005297-A1 | BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | NANTBIO, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| CN-101641335-A | Amino-5-[substituted-4-(difluoromethoxy)phenyl]-5- phenylimidazolone compounds as ss-secretase inhibitors | WYETH CORP US | 2010-02-03 | — | — | CN | disclosed |
| EP-2137161-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008115552-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008115552-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210101879-A1 | AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIs) FOR ALZHEIMER?S DISEASE | APP, BACE1, BACE2 | ALDH1A1 4154/4885MEN1 3585/4885MAPT 7/4885 |
| US-20200165225-A1 | BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN2 | ALDH1A1 1313/4885MEN1 3735/4885MAPT 10/4885 |
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, APP | ALDH1A1 2270/4885MEN1 3838/4885MAPT 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.